CompletedPhase 1NCT03841110
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Studying Alpha-heavy chain disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fate Therapeutics
- Principal Investigator
- Fate Trial DisclosureFateTrialDisclosure@fatetherapeutics.com
- Intervention
- FT500(drug)
- Enrollment
- 37 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2022
Study locations (4)
- UCSD Moores Cancer Center, San Diego, California, United States
- University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
- Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03841110 on ClinicalTrials.gov